Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis

Peritoneal Dialysis International

Volumn 24, Issue 5, 2004, Pages 447-453

  Yeung, Sharon M ^a,b   Walker, Scott E ^a   Tailor, Sandra A N ^a   Awdishu, Linda ^a   Tobe, Sheldon ^a   Yassa, Teraiza ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Automated peritoneal dialysis; Ciprofloxacin; Continuous cycling peritoneal dialysis (CCPD); Peritonitis; Pharmacokinetics

Indexed keywords

CIPROFLOXACIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD SAMPLING; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTINUOUS CYCLING PERITONEAL DIALYSIS; CONTROLLED STUDY; DIALYSATE; DIALYSATE LEVEL; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; EMPIRICISM; ESCHERICHIA COLI; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KLEBSIELLA; MALAISE; MALE; MEDICAL DOCUMENTATION; MINIMUM INHIBITORY CONCENTRATION; NAUSEA AND VOMITING; NONHUMAN; PERITONEAL DIALYSIS; PERITONITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

EID: 7444272596     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080402400509     Document Type: Article

References (20)

1. Brophy DF, Mueller BA. Automated peritoneal dialysis: new implications for pharmacists. Ann Pharmacother 1997; 31:756-64.
2. Johnson CC, Baldessarre J, Levison ME. Peritonitis: update on pathophysiology, clinical manifestations, and management. Clin Infect Dis 1997; 24:1035-47.
3. Troidle L, Gorban-Brennan N, Kliger AS, Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32:623-8.
4. Shermin D, Maaz D, St. Pierre D, Kahn SI, Chazan JA. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients. Am J Kidney Dis 1999; 34:14-20.
5. Baker RJ, Senior H, Clemenger M, Brown EA. Empirical aminoglycosides for peritonitis do not affect residual renal function. Am J Kidney Dis 2003; 41:670-5.
6. Churchill DN, Taylor DW, Keshaviah PR. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7:198-207.
7. ISPD Guidelines/Recommendations. Adult peritoneal dialysis-related peritonitis treatment recommendations: 2000 update. Available from: http://www.ispd.org [accessed February 2001].
8. Rains CP, Bryson HM, Peters DH. Ceftazidime: an update of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1995; 49:577-617.
9. Janknegt R. CAPD peritonitis and fluoroquinolones: a review. Perit Dial Int 1991; 11:48, 53-8.
10. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986; 39:489-90.
11. Nikolaidis P, Walker SE, Dombros N, Tourkantonis A, Paton TW, Oreopoulos DG. Single dose pefloxacin pharmacokinetics and metabolism in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Perit Dial Int 1991; 11:59-63.
12. Myers CM, Blumer JL. High-performance liquid chromatography of ciprofloxacin and its metabolites in serum, urine and sputum. J Chromatogr 1987; 422: 153-64.
13. Griggs DJ, Wise R. A simple isocratic high-pressure liquid chromatographic assay of quinolones in serum. J Antimicrob Chemother 1989; 24:437-45.
14. Rowland M, Tozer TN. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 1995.
15. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-81.
16. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27:33-9.
17. Fleming LW, Moreland TA, Scott AC, Stewart WK, White LO. Ciprofloxacin in plasma and peritoneal dialysate after oral therapy in patients on continuous ambulatory peritoneal dialysis. J Antimicrob Chemother 1987; 19:493-503.
18. Kowalsky SF, Echols M, Schwartz MT, Bailie GR, McCormick E. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD. Clin Nephrol 1993; 39:53-8.
19. Shalit I, Greenwood RB, Marks MI, Pederson JA, Frederick DL. Pharmacokinetics of single-dose oral ciprofloxacin in patients undergoing chronic ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1986; 30:152-6.
20. Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F. Once-daily intraperitoneal cefazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis. Adv Perit Dial 1999; 15:213-16.